Skip to content

Prospective Collection of Whole Blood Specimens From RhD Negative Pregnant Women

Prospective Collection of Whole Blood Specimens From RhD Negative Pregnant Women

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06690099
Enrollment
500
Registered
2024-11-15
Start date
2025-04-07
Completion date
2027-01-01
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Rhesus D Genotype

Keywords

RhD negative, fetal DNA, cell free fetal DNA, Fetal RhD genotype

Brief summary

The purpose of this research is to collect blood samples and data from pregnant women who are Rh negative. The blood will be used for the future research and the development of non-invasive prenatal tests to identify Rh blood type status of the baby during pregnancy.

Detailed description

This is a prospective multi-center blood collection study. Women 18 years of age or older with a viable singleton pregnancy between12 weeks and 28 weeks gestation will be enrolled. Whole blood samples will be collected from each enrolled patient. Maternal specimens will be processed to plasma and stored for future testing with non-invasive prenatal tests to identify fetal Rh status. Baby RhD blood type status will be recorded after delivery. All obstetric clinical management will take place per standard clinic practices and procedures and will not be altered by participation in the study.

Interventions

None listed

Sponsors

Devyser Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Willing and able to provide written informed consent 2. 18 years of age or older at enrollment 3. Women with a viable pregnancy (with documented fetal heartbeat) between 12 weeks, 0 days and 28 weeks, 0 days gestational age 4. Women with RhD negative antigen status by serology 5. Willing to provide neonatal ABO and RhD genotyping status

Exclusion criteria

1\. Women with multiple gestation pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Fetal RhD determination from maternal whole blood18 monthsCollected samples will be used for future development of non-invasive prenatal test to determine fetal RhD status from maternal whole blood

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026